Ultragenyx Pharmaceutical Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Emil D. Kakkis
- Full Time Employees
- 1,371
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 60 Leveroni Court Novato CA United States of America 94949
- IPO Date
- Jan 31, 2014
- CIK
- 0001515673
- Website
- ultragenyx.com
- Similar Companies
- Business
- Ultragenyx Pharmaceutical Inc. (Nasdaq: RARE) is a biopharmaceutical company focused on the development and commercialization of innovative therapies for rare and ultrarare genetic diseases. Founded in 2010 and headquartered in Novato, California, the company offers approved products including Crysvita (burosumab) for X-linked hypophosphatemia and tumor-induced osteomalacia; Mepsevii for mucopolysaccharidosis VII; and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders; alongside a robust pipeline targeting conditions such as Angelman syndrome with GTX-102. Ultragenyx operates globally, with commercial presence in North America, Europe, and select international markets, serving patients through specialized support programs like UltraCare. In recent developments, Ultragenyx sold a portion of future North American royalties on Crysvita to OMERS Life Sciences for $400 million in November 2025; reported third quarter 2025 financial results with total revenue guidance of $640 million to $670 million; dosed the first patient in the Aurora study for GTX-102 in Angelman syndrome in October 2025; and appointed Eric Olson as Chief Business Officer in September 2025.
Company News
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Stock Has Consensus Price Target of $34.58 According to Analysts
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
JAGUAR URANIUM REPORTS RARE EARTH OXIDES ASSOCIATED WITH URANIUM-PHOSPHATE-VANADIUM MINERALIZATION AT THE BERLIN ASSET IN COLOMBIA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
ULTRA-RARE MCA CENTENAIRE, MONACO'S FIRST SUPERCAR, OFFERED AT BROAD ARROW'S 2026 ZOUTE CONCOURS AUCTION
RARE Stock Up 13% on FDA Approval of Sanfilippo Syndrome Gene Therapy
Ultragenyx (RARE) Surges 12.6%: Is This an Indication of Further Gains?
Abeona Stands to Collect Royalties After Ultragenyx's FDA Approval — Here's the Rest of the Week
Ultragenyx Pharmaceutical Inc. (RARE) Discusses FDA Approval of FAYUVI as First Treatment for Sanfilippo Syndrome Type A Transcript
Ultragenyx Announces Approval of FAYUVI™ Gene Therapy, the First-Ever FDA-Approved Treatment for Sanfilippo Syndrome Type A (MPS IIIA)
US FDA approves Ultragenyx's gene therapy for rare disorder
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
Why Is Ultragenyx (RARE) Up 6.4% Since Last Earnings Report?
RARE Stock Down 46% as Phase III Angelman Syndrome Study Misses Goals
QUICK SPARK: Pharma Bro Martin Shkreli Says Ultragenyx Should Be M&A Target
Ultragenyx Forced To Cut Costs After Disappointing Phase 3 Results
Here Are Thursday’s Top Wall Street Analyst Research Calls: Broadcom, Deere & Company, Dell Technologies, Devon Energy, Moderna, Permian Resources, PG&E, Thermo Fisher, Viper Energy, and More
Ultragenyx Stock Sinks 47% on Drug Trial Failure. Why Wall Street Isn't Giving Up Yet.